Zimbabwe has turned down a major American healthcare agreement valued at 367 million US dollars (£272m) over five years due to the United States' insistence on confidential biological samples.
The decision became public following a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
A government spokesperson has since clarified that the US was requesting health data for research and profit but was not willing to guarantee the benefits from any future treatments.
"We will now turn to the difficult and regrettable process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued talks to find a deal acceptable to both sides so the nation's critical HIV programme can be sustained.
Broader Implications
This development comes after a comparable case in Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance openness and accountability.
Based on statements, Sixteen African countries have to date signed these new health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration could have provided significant benefits for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy via American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, without any corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our population should a new pandemic emerge."
National Interest and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were upending systems previously set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This mechanism is designed to ensure that when a nation provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how future co-operation might be designed in a way that honours the sovereignty and interests of both nations."
Medical Community Response
Medical experts said it acknowledged the government's concerns, but urged that talks need to persist since a large portion of the country's HIV programmes were funded by international support.
"If technical issues arise, including those relating to data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
This impasse highlights the ongoing debate between accepting crucial international aid and safeguarding a country's data in an increasingly data-driven world.